CombiMatrix Launches CustomArray(TM) 90K High-Density Array and CustomArray 90K Synthesizer

BIOWIRE2K
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--May 9, 2006--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group has launched the next-generation CustomArray(TM) and CustomArray(TM) Synthesizer, providing researchers with the ability to fabricate the new CustomArray(TM) 90K. This high-density, customizable, re-usable microarray has over 94,000 unique DNA probes. The CustomArray 90K enables CombiMatrix to completely serve the entire research market with whole-genome gene expression, SNP genotyping, comparative genomic hybridization (CGH), tiling, ChIP-on-chip, and resequencing.

"The CustomArray 90K coupled with the CustomArray 90K Synthesizer is a perfect solution for those who want high-quality, re-usable commercial microarrays, while having complete supply control, flexibility, and low manufacturing costs," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "We are now preparing for the launch of the world's most-up-to-date whole-human-genome array in addition to an expanded catalog of model-organism-based whole-genome arrays."

“We are now preparing for the launch of the world's most-up-to-date whole-human-genome array in addition to an expanded catalog of model-organism-based whole-genome arrays.”

COMBIMATRIX CUSTOMARRAYS(TM)

CustomArrays are semiconductor-based arrays (approx. 1 cm2) integrated onto a standard 1" x 3" slide format. CustomArrays contain in situ synthesized oligonucleotides, prepared using CombiMatrix's patented virtual-flask technology. Sensitivity and performance metrics are available from the company's web site and at www.customarray.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts

Acacia Research Corporation
Bret L. Undem (Media Relations), 425-493-2293
Fax: 425-493-2010

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.